MedTrace Logo

Long-Term Follow-Up of Patients Who Received Gene-Modified Cell Therapy

NCT05472649 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2023-01-23

No results posted yet for this study

Summary

Observational long-term follow-up study of patients who have been exposed to a gene-modified cell therapy produced by ex vivo transduction of immune cells expressing viral or non-viral vectors in studies sponsored by Sorrento Therapeutics, Inc.

Conditions

  • Long-term Follow-up

Interventions

BIOLOGICAL

Gene-Modified Cell Therapy

No investigational cell product will be administered

Sponsors & Collaborators

  • Sorrento Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Mike Royal, MD · Sorrento Therapeutics, Inc.

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-16
Primary Completion
2036-12-31
Completion
2037-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05472649 on ClinicalTrials.gov